ARTICLE | Product Development
COVID-19 roundup: Can-Fite repurposing RA therapy; plus Brazilian chloroquine study points to cardiotoxicity, Athersys stem cell trial, Rutgers saliva test
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 14, 2020 1:22 AM UTC
Updated on Apr 14, 2020 at 1:34 AM UTC
As Can-Fite begins testing the first ADORA3 agonist against COVID-19, the latest red flag for chloroquine came with the immediate termination of the high dose arm of a Brazilian trial of the repurposed malaria drug.
Other companies moving therapeutics forward include Athersys, which has gained FDA’s backing to start a pivotal trial of its cell therapy to treat moderate to severe COVID-19...
BCIQ Target Profiles